Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John R W Masters

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Anticancer Research|June 28, 2007
Clinical applications of expression profiling and proteomics in prostate cancerJohn R W Masters
Nature Reviews. Cancer|July 2, 2003
Curing metastatic cancer: lessons from testicular germ-cell tumoursJohn R W Masters, Beate Köberle
Molecular Carcinogenesis|February 2, 2008
Elevation of XPA protein level in testis tumor cells without increasing resistance to cisplatin or UV radiationBeate Köberle, Vera Roginskaya, Karen S Zima, et al.
Cellular Signalling|April 22, 2008
A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGFTasneem Ahmed, Kerry Shea, John R W Masters, et al.
Journal of Cell Science|April 22, 2010
PAK4: a pluripotent kinase that regulates prostate cancer cell adhesionClaire M Wells, Andrew D Whale, Maddy Parsons, et al.
BJU International|July 27, 2005
Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of <10 ng/mLAlison J Birtle, Alex Freeman, John R W Masters, et al.
Cancer|November 25, 2003
Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the "PSA negative" patientsAlison J Birtle, Alex Freeman, John R W Masters, et al.
International Journal of Cancer|April 20, 2004
Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell linesCarey Welsh, Roger Day, Claire McGurk, et al.
Plos One|May 11, 2010
A novel role for Wnt/Ca2+ signaling in actin cytoskeleton remodeling and cell motility in prostate cancerQin Wang, Andrew J Symes, Corrina A Kane, et al.
The Journal of Pathology|April 15, 2003
Can p53 staining be used to identify patients with aggressive superficial bladder cancer?John R W Masters, Urvi D Vani, Kenneth M Grigor, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Anticancer Research|June 28, 2007
Clinical applications of expression profiling and proteomics in prostate cancerJohn R W Masters
Nature Reviews. Cancer|July 2, 2003
Curing metastatic cancer: lessons from testicular germ-cell tumoursJohn R W Masters, Beate Köberle
Molecular Carcinogenesis|February 2, 2008
Elevation of XPA protein level in testis tumor cells without increasing resistance to cisplatin or UV radiationBeate Köberle, Vera Roginskaya, Karen S Zima, et al.
Cellular Signalling|April 22, 2008
A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGFTasneem Ahmed, Kerry Shea, John R W Masters, et al.
Journal of Cell Science|April 22, 2010
PAK4: a pluripotent kinase that regulates prostate cancer cell adhesionClaire M Wells, Andrew D Whale, Maddy Parsons, et al.
BJU International|July 27, 2005
Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of <10 ng/mLAlison J Birtle, Alex Freeman, John R W Masters, et al.
Cancer|November 25, 2003
Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the "PSA negative" patientsAlison J Birtle, Alex Freeman, John R W Masters, et al.
International Journal of Cancer|April 20, 2004
Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell linesCarey Welsh, Roger Day, Claire McGurk, et al.
Plos One|May 11, 2010
A novel role for Wnt/Ca2+ signaling in actin cytoskeleton remodeling and cell motility in prostate cancerQin Wang, Andrew J Symes, Corrina A Kane, et al.
The Journal of Pathology|April 15, 2003
Can p53 staining be used to identify patients with aggressive superficial bladder cancer?John R W Masters, Urvi D Vani, Kenneth M Grigor, et al.
Pageof 2